Floatz logo

Metformin

Multiple Sclerosis (MS) - Relapsing-remitting

German University in CairoSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

79 Active assets in the Multiple Sclerosis (MS) - Relapsing-remitting cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB

View all 50 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →